Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

MAPT Protocol: Trattamenti Chirurgici di Fissazione Versus Artroplastica per un Recupero Precoce Dopo Frattura dell'ANCA (FASTER-HIP) (FASTER-HIP)

5 novembre 2026 aggiornato da: Joseph Patterson, University of Southern California

Studio di Piattaforma Adattiva Muscoloscheletrica (MAPT): Trattamenti Chirurgici di Fissazione Versus Artroplastica per il Recupero Precoce Dopo Frattura dell'ANCA (FASTER-HIP)

This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.

Panoramica dello studio

Descrizione dettagliata

The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.

Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.

FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.

Tipo di studio

Interventistico

Iscrizione (Stimato)

600

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Ottawa, Canada, K1H 8L6
        • Non ancora reclutamento
        • The Ottawa Hospital
        • Contatto:
        • Investigatore principale:
          • Bradley Meulenkamp, MD
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z4
        • Reclutamento
        • University of British Columbia
        • Contatto:
          • Aresh Sepehri, MD
        • Contatto:
        • Investigatore principale:
          • Aresh Sephri, MD
      • Vancouver, British Columbia, Canada
        • Reclutamento
        • Fraser Health Authority
        • Contatto:
        • Contatto:
          • Numero di telefono: 604-777-5577
        • Investigatore principale:
          • Darius Viskontas, MD
    • Ontario
      • London, Ontario, Canada, N6A 5W9,
        • Reclutamento
        • London Health Sciences Centre
        • Contatto:
        • Investigatore principale:
          • Emil Schemitsch, MD
      • Grålum, Norvegia, 1714
        • Reclutamento
        • Sykehuset Østfold HF / Østfold Hospital Trust
        • Contatto:
          • Frede Frihagen, MD
        • Contatto:
        • Investigatore principale:
          • Frede Frihagen, MD
      • Edinburgh, Regno Unito, EH8 8BG
      • Barcelona, Spagna
        • Non ancora reclutamento
        • Hospital Universitari Vall d'Hebron
        • Contatto:
        • Investigatore principale:
          • Carlos Alberto Piedra-Calle, MD
      • Barcelona, Spagna
        • Non ancora reclutamento
        • Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG)
        • Investigatore principale:
          • Alfred Dealbert, MD
        • Contatto:
      • Barcelona, Spagna, 08221
        • Non ancora reclutamento
        • Hospital Universitario Mutua de Terrassa
        • Contatto:
        • Investigatore principale:
          • Pablo Castillon Bernal, MD
      • Barcelona, Spagna
        • Non ancora reclutamento
        • FRCB-IDIBAPS (Hospital Clinic Barcelona)
        • Contatto:
        • Investigatore principale:
          • Pilar Camacho, MD
    • California
      • Irvine, California, Stati Uniti, 92660
        • Reclutamento
        • University of California, Irvine
        • Investigatore principale:
          • Gerard Slobogean, MD
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90048
        • Reclutamento
        • Cedars-Sinai Medical Center
        • Investigatore principale:
          • Carol Lin, MD
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • University of Southern California
        • Investigatore principale:
          • Joshua L Gary, MD
        • Contatto:
      • Los Angeles, California, Stati Uniti, 90033
        • Reclutamento
        • Los Angeles General Medical Center
        • Investigatore principale:
          • Joshua L Gary, MD
        • Contatto:
      • San Francisco, California, Stati Uniti, 94143
        • Reclutamento
        • University of California San Francisco
        • Investigatore principale:
          • Saam Morshed, MD
        • Contatto:
    • Florida
      • Miami, Florida, Stati Uniti, 33146
        • Non ancora reclutamento
        • University of Miami
        • Contatto:
        • Investigatore principale:
          • Giselle Hernandez, MD
    • Indiana
      • Bloomington, Indiana, Stati Uniti, 47405
        • Reclutamento
        • Indiana University
        • Investigatore principale:
          • Dillon O'Neill, MD
        • Contatto:
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201
        • Reclutamento
        • University of Maryland, Baltimore - R Adams Cowley Shock Trauma Center
        • Investigatore principale:
          • Mark Gage, MD
        • Contatto:
      • Largo, Maryland, Stati Uniti, 20774
        • Reclutamento
        • University of Maryland Capital Region Health
        • Investigatore principale:
          • Todd Jaeblon, MD
        • Contatto:
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Non ancora reclutamento
        • Beth Israel Deaconess Medical Center
        • Contatto:
        • Investigatore principale:
          • Ishaq Ibrahim, MD
      • Boston, Massachusetts, Stati Uniti, 02115
        • Reclutamento
        • Massachusetts General Brigham
        • Contatto:
        • Investigatore principale:
          • Michael Weaver, MD
    • Mississippi
      • University, Mississippi, Stati Uniti, 38677
        • Reclutamento
        • University of Mississippi
        • Investigatore principale:
          • Patrick Bergin, MD
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10016
        • Reclutamento
        • NYU Langone Health
        • Investigatore principale:
          • Ran Schwarzkopf, MD
        • Contatto:
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45221
        • Reclutamento
        • University of Cincinnati
        • Contatto:
        • Investigatore principale:
          • Michael Beltran, MD
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • Reclutamento
        • University of Oklahoma Health Sciences Center
        • Investigatore principale:
          • Brandon Hull, MD
        • Contatto:
    • Pennsylvania
      • Allentown, Pennsylvania, Stati Uniti, 18102
        • Reclutamento
        • St. Luke's University Health System
        • Investigatore principale:
          • Dustin Greenhill, MD
        • Contatto:
    • South Carolina
      • Greenville, South Carolina, Stati Uniti, 29601
        • Reclutamento
        • Prisma Health-Upstate
        • Investigatore principale:
          • Kyle Jeray, MD
        • Contatto:
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37235
        • Reclutamento
        • Vanderbilt University
        • Contatto:
        • Investigatore principale:
          • Lauren Tatman, MD
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84108
        • Reclutamento
        • University of Utah
        • Investigatore principale:
          • Lucas Marchand, MD
        • Contatto:
    • Vermont
      • Burlington, Vermont, Stati Uniti, 05405
        • Non ancora reclutamento
        • University of Vermont
        • Contatto:
        • Investigatore principale:
          • Michael Blankstein, MD
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Reclutamento
        • Inova Health Care Services
        • Investigatore principale:
          • Greg Gaski, MD
        • Contatto:
    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53706
        • Reclutamento
        • University of Wisconsin - Madison
        • Investigatore principale:
          • Chris Domes, MD
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

60 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
  • The patient has a health condition affecting physical mobility.
  • Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
  • Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
  • Low energy injury mechanism.
  • Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.

Exclusion Criteria:

  • The patient is not clinically suitable for either compared treatment.
  • Expected injury survival of less than 12 months.
  • Terminal illness with expected survival of less than 12 months.
  • Incarceration.
  • Unable to obtain informed consent due to language barriers.
  • Unable to obtain informed consent because the legally authorized representative was unavailable.
  • Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.
  • Currently enrolled in a study or intervention domain that does not permit co-enrollment.
  • Prior enrollment in the specific platform trial intervention domain.
  • Patient or legally authorized representative did not provide informed consent (declined participation).
  • Eligible patient or legally authorized representative was not approached within the screening window (missed participant).
  • Other reasons to exclude the patient, as approved by the data coordinating center.
  • Associated lower extremity injury that prevents post-operative weight-bearing.
  • Retained hardware around the hip that precludes either study treatment.
  • Infection around the hip (soft tissue or bone).
  • Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
  • Injury did not occur within 21 days of screening.
  • Patient is too ill, in the judgment of the attending surgeon, for internal fixation.
  • Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Artroplastica dell'anca

Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon.

Comparatore attivo: Fissazione interna

Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Composite outcome of death, ambulation status, and days alive and out of hospital.
Lasso di tempo: 120 days after randomization

Death consists of time to all-cause mortality.

Ambulation will be evaluated using an ordinal ranking of independence.

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
120 days after randomization

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Composite outcome of death, ambulation status, and days alive and out of hospital.
Lasso di tempo: 365 days after randomization

Death consists of time to all-cause mortality.

Ambulation will be evaluated using an ordinal ranking of independence.

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
365 days after randomization
Death
Lasso di tempo: 120 days post-randomization

Death consists of time to all-cause mortality.

120 days post-randomization
Death
Lasso di tempo: 12 months post-randomization

Death consists of time to all-cause mortality.

12 months post-randomization
Ambulation status
Lasso di tempo: 120 days post-randomization

Ambulation will be evaluated using an ordinal ranking of independence

120 days post-randomization
Ambulation status
Lasso di tempo: 12 months post-randomization

Ambulation will be evaluated using an ordinal ranking of independence

12 months post-randomization
Days alive and out of hospital
Lasso di tempo: 120 days post-randomization

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
120 days post-randomization
Days alive and out of hospital
Lasso di tempo: 12 months post-randomization

Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:

  • Days not alive.
  • Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.
12 months post-randomization
Health-related quality of life
Lasso di tempo: 120 days days post-randomization

EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health

120 days days post-randomization
Health-related quality of life
Lasso di tempo: 12 months post-randomization

EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health

12 months post-randomization
Numeric Pain Rating Scale
Lasso di tempo: During hospitalization in the first seven postoperative days

The highest level of pain recorded daily in the participant's medical record - Range: 0-10, higher score indicates higher level of pain

During hospitalization in the first seven postoperative days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Joseph T Patterson, MD, University of Southern California

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

23 gennaio 2026

Completamento primario (Stimato)

28 febbraio 2029

Completamento dello studio (Stimato)

31 gennaio 2030

Date di iscrizione allo studio

Primo inviato

31 ottobre 2025

Primo inviato che soddisfa i criteri di controllo qualità

19 novembre 2025

Primo Inserito (Effettivo)

24 novembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi